All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
Introducing
Now you can personalise
your MPN Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Among patients with newly diagnosed myeloproliferative neoplasms (MPN), 10–20% are of fertile age, and pregnancy in patients with MPN may pose fetal and maternal complications, such as maternal thrombosis, hemorrhage, and placental dysfunction.1
The live birth rates in pregnant women with polycythemia vera or essential thrombocytosis are reported to be 65% and 70%, respectively.1 Although prospective studies have reported a higher live birth rate in pregnant women with MPN, these studies have been limited by small patient numbers and further systematic studies are limited by the infrequent occurrence of pregnancies in such patients.1
Here, we present a visual abstract representing the key findings from a large population-based study of pregnant women with MPN in Sweden and the associated neonatal and maternal adverse events, which were published by Landtblom, et al.1 in Leukemia.
Your opinion matters
Subscribe to get the best content related to MPN delivered to your inbox